This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, Y. Articles by Mao, Y. Search for Related Content PubMed PubMed Citation Articles by Chen, Y. Articles by Mao, Y.

Epidemiology of Contralateral Breast Cancer¹

Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa [Y. C., W. T.], and Cancer Bureau, Laboratory Centre for Disease Control, Health Canada, Ottawa, Ontario, Canada K1H 8M5 [R. S., Y. M.]

Two to 11% of women diagnosed with breast cancer will develop contralateral breast cancer in their lifetime. Women with a first primary are at a 2–6-fold increased risk of developing contralateral breast cancer compared with the risk in the general population of women developing a first primary cancer. The incidence rate of contralateral breast cancer varies from four to eight per 1000 person-years. To assess the risk factors associated with the development of contralateral breast cancer among women with a first primary breast cancer, the epidemiological literature concerning these factors was reviewed and summarized. Studies have shown that a family history of breast cancer, an early age at initial diagnosis, and a lobular histology of the first primary breast cancer increase the risk of developing contralateral breast cancer. Although chemotherapy and tamoxifen therapy may reduce this risk, there are inconsistent results regarding the effects of radiotherapy and the effects of reproductive, environmental and other factors. Additional analytical studies addressing all potential risk factors associated with the development of contralateral breast cancer are necessary in view of the increasing incidence and survival of women with a first primary.

This article has been cited by other articles:

				L. Bertelsen, L. Bernstein, J. H. Olsen, L. Mellemkjaer, R. W. Haile, C. F. Lynch, K. E. Malone, H. Anton-Culver, J. Christensen, B. Langholz, et al. Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology Study J Natl Cancer Inst, January 2, 2008; 100(1): 32 - 40. [Abstract] [Full Text] [PDF]

				M. Hartman, K. Czene, M. Reilly, J. Adolfsson, J. Bergh, H.-O. Adami, P. W. Dickman, and P. Hall Incidence and Prognosis of Synchronous and Metachronous Bilateral Breast Cancer J. Clin. Oncol., September 20, 2007; 25(27): 4210 - 4216. [Abstract] [Full Text] [PDF]

				F. Pediconi, C. Catalano, A. Roselli, S. Padula, F. Altomari, E. Moriconi, A. M. Pronio, M. A. Kirchin, and R. Passariello Contrast-enhanced MR Mammography for Evaluation of the Contralateral Breast in Patients with Diagnosed Unilateral Breast Cancer or High-Risk Lesions Radiology, June 1, 2007; 243(3): 670 - 680. [Abstract] [Full Text] [PDF]

				J. A. Largent, M. Capanu, L. Bernstein, B. Langholz, L. Mellemkjaer, K. E. Malone, C. B. Begg, R. W. Haile, C. F. Lynch, H. Anton-Culver, et al. Reproductive History and Risk of Second Primary Breast Cancer: The WECARE Study Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 906 - 911. [Abstract] [Full Text] [PDF]

				K. Hemminki, J. Ji, and A. Forsti Risks for Familial and Contralateral Breast Cancer Interact Multiplicatively and Cause a High Risk Cancer Res., February 1, 2007; 67(3): 868 - 870. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				J. Bonneterre, H. Roche, P. Kerbrat, A. Bremond, P. Fumoleau, M. Namer, M.-J. Goudier, S. Schraub, P. Fargeot, and I. Chapelle-Marcillac Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial J. Clin. Oncol., April 20, 2005; 23(12): 2686 - 2693. [Abstract] [Full Text] [PDF]

				W. McCaskill-Stevens, J. Wilson, J. Bryant, E. Mamounas, L. Garvey, J. James, W. Cronin, and D. L. Wickerham Contralateral Breast Cancer and Thromboembolic Events in African American Women Treated With Tamoxifen J Natl Cancer Inst, December 1, 2004; 96(23): 1762 - 1769. [Abstract] [Full Text] [PDF]

				M. D. Schwartz, C. Lerman, B. Brogan, B. N. Peshkin, C. Hughes Halbert, T. DeMarco, W. Lawrence, D. Main, C. Finch, C. Magnant, et al. Impact of BRCA1/BRCA2 Counseling and Testing on Newly Diagnosed Breast Cancer Patients J. Clin. Oncol., May 15, 2004; 22(10): 1823 - 1829. [Abstract] [Full Text] [PDF]

				J. N. Weitzel, S. M. McCaffrey, R. Nedelcu, D. J. MacDonald, K. R. Blazer, and C. A. Cullinane Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer Diagnosis Arch Surg, December 1, 2003; 138(12): 1323 - 1328. [Abstract] [Full Text] [PDF]

				T. Bachleitner-Hofmann, B. Pichler-Gebhard, M. Rudas, M. Gnant, S. Taucher, D. Kandioler, E. Janschek, P. Dubsky, S. Roka, E. Sporn, et al. Pattern of Hormone Receptor Status of Secondary Contralateral Breast Cancers in Patients Receiving Adjuvant Tamoxifen Clin. Cancer Res., November 1, 2002; 8(11): 3427 - 3432. [Abstract] [Full Text] [PDF]

				C. I. Li, K. E. Malone, N. S. Weiss, and J. R. Daling Tamoxifen Therapy for Primary Breast Cancer and Risk of Contralateral Breast Cancer J Natl Cancer Inst, July 4, 2001; 93(13): 1008 - 1013. [Abstract] [Full Text] [PDF]